Bioverativ Therapeutics Inc.

Puget Sound Blood Center

Cellarity, Inc.

Sriram Krishnamoorthy

Haiyan Jiang

Glenn Pierce

Tongyao Liu

Neil Josephson

Qing Tang

Atli Thorarensen

Na Li

Ravi Ujjinamatada

Mauricio Cortes

Robert Brian Nicewonger

Kristen Marino

David Zhang

Colin Diner

Samuel Miller

Frank Lovering

Ragy Haddad

Pierce Glenn

The present disclosure provides DCN-1 modulating compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions, and their use for treating sickle cell disorders, diseases, and conditions. Such compounds are of Formula I: or a pharmaceutically acceptable salt thereof.

DCN-1 modulating compounds and methods of use thereof

The present disclosure provides DCN-1 modulating compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions, and their use for treating sickle cell disorders, diseases, and conditions. Such compounds are of Formula Ia: or a pharmaceutically acceptable salt thereof.

Modulators of DCN-1 and methods of use thereof

The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

Growing community of inventors

Medford, MA, United States of America

Sriram Krishnamoorthy